Previous studies have demonstrated that genetic lesions of the PIK3CA gene drive such consecutive activation of the PI3K/Akt/mTOR pathway that not only sustain the in the tumor cells’ survival, proliferation and metastasis but also trigger the breast cancer cells to become resistant to the conventional endocrine therapy [9]. This evidence concerns the gene AKT1 and breast cancer.